close 74% rachunków inwestorów detalicznych odnotowuje straty w wyniku handlu kontraktami CFD u niniejszego dostawcy. Inwestowanie wiąże się z ryzykiem i nie jest odpowiednie dla wszystkich inwestorów. Kontrakty CFD są złożonymi instrumentami i wiążą się z dużym ryzykiem szybkiej utraty środków pieniężnych z powodu dźwigni finansowej. 74% rachunków inwestorów detalicznych odnotowuje straty w wyniku handlu kontraktami CFD u niniejszego dostawcy. Upewnij się, czy rozumiesz, jak działają kontrakty CFD, i czy możesz pozwolić sobie na wysokie ryzyko utraty pieniędzy.
Change languagePolski
Pulpit

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

Strona główna・Stock List・Karyopharm Therapeutics Inc
Search

Karyopharm Therapeutics Inc

Closed

SectorHealthcare

8.2 -3.3

Strong Buy

Price update 10 mar 2026, 19:59 UTC

BuySell

Overview

Share price change

24h

Current

Min

8.14

Max

8.8

Key metrics

By Trading Economics

Income

-69M

-102M

Sales

-10M

34M

EPS

-5.69

Profit margin

-299.886

Employees

228

EBITDA

4.7M

-18M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+129.68% upside

Market Stats

By TradingEconomics

Market Cap

-1.4M

156M

Previous open

11.5

Previous close

8.2

News Sentiment

By Acuity

75%

25%

316 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

5.9501 / 7.66 Support & Resistance

Karyopharm Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 mar 2026, 20:38 UTC

Earnings

Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring

DJ

Read

10 mar 2026, 23:57 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Read

10 mar 2026, 23:57 UTC

Market Talk

Risks Rising on Australian Bank Valuation Multiples -- Market Talk

DJ

Read

10 mar 2026, 23:47 UTC

Market Talk

Nikkei May Rise as Concerns About Energy Costs Ease -- Market Talk

DJ

Read

10 mar 2026, 23:37 UTC

Acquisitions, Mergers, Takeovers

Yangzijiang Shipbuilding to Acquire Poseidon Stake for US$825.7M

DJ

Read

10 mar 2026, 23:37 UTC

Acquisitions, Mergers, Takeovers

Yangzijiang Shipbuilding to Buy 10% Stake in Poseidon

DJ

Read

10 mar 2026, 23:37 UTC

Acquisitions, Mergers, Takeovers

Yangzijiang Shipbuilding to Fund Deal With Internal Cash Resources

DJ

Read

10 mar 2026, 23:37 UTC

Acquisitions, Mergers, Takeovers

Yangzijiang Shipbuilding to Buy Stake From Fairfax, Washington Family Affiliates

DJ

Read

10 mar 2026, 23:35 UTC

Market Talk
Major News Events

Gold Edges Higher as It Faces Opposing Forces -- Market Talk

DJ

Read

10 mar 2026, 23:06 UTC

Earnings

Oracle Raises 2027 Sales View as AI Demand Outpaces Supply -- Update

DJ

Read

10 mar 2026, 22:51 UTC

Major News Events

Deleted Tweet From Energy Secretary Sends Oil Markets on Another Wild Ride -- Updated

DJ

Read

10 mar 2026, 21:39 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman Has a Stroke of Genius. Buy His New Fund and Get Shares of His Pershing Square IPO. -- Barrons.com

DJ

Read

10 mar 2026, 21:21 UTC

Earnings

Oracle Stock Jumps on Earnings Beat. Its Cloud Business Is Taking Over. -- Barrons.com

DJ

Read

10 mar 2026, 21:15 UTC

Earnings

Franco-Nevada: 2026 Total GEOs Expected to Range From 510,000 to 570,000 Ounces

DJ

Read

10 mar 2026, 21:15 UTC

Acquisitions, Mergers, Takeovers

Paramount Skydance's Stock Fades. The Warner Bros. Merger Will Take Years to Pay Off, BofA Says. -- Barrons.com

DJ

Read

10 mar 2026, 21:14 UTC

Earnings

Franco-Nevada: Methodology Replaces Previous Variable GEO Conversion Ratios Based on Prevailing Market Prices

DJ

Read

10 mar 2026, 21:13 UTC

Earnings

Franco-Nevada: Beginning in 2026, Company Will Be Adopt Fixed GEO Conversion Ratios Based on the Pricing Assumptions Outlined in 2026 Guidance

DJ

Read

10 mar 2026, 21:12 UTC

Earnings

Franco-Nevada 4Q Rev $597.3M >FNV

DJ

Read

10 mar 2026, 21:12 UTC

Earnings

Franco-Nevada 4Q EPS $1.90

DJ

Read

10 mar 2026, 20:57 UTC

Earnings

Oracle Stock Jumps on Earnings Beat -- Barrons.com

DJ

Read

10 mar 2026, 20:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

DJ

Read

10 mar 2026, 20:44 UTC

Earnings

Oracle Stock Jumps on Earnings Beat -- Barrons.com

DJ

Read

10 mar 2026, 20:34 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

DJ

Read

10 mar 2026, 20:34 UTC

Market Talk
Earnings

Oracle Building More Software for Less Money After Restructuring -- Market Talk

DJ

Read

10 mar 2026, 20:23 UTC

Earnings

Oracle Stock Jumps on Earnings Beat -- Barrons.com

DJ

Read

10 mar 2026, 20:16 UTC

Earnings

NIO Stock Jumps After Earnings. How the EV Maker Delivered a Surprise Profit. -- Barrons.com

DJ

Read

10 mar 2026, 20:14 UTC

Earnings

Oracle Has Not Yet Initiated At-The-Market Equity Portion of Financing Program >ORCL

DJ

Read

10 mar 2026, 20:14 UTC

Earnings

Oracle Said In February It Intends to Raise Up to $50 B Dollars in Debt and Equity Financing >ORCL

DJ

Read

10 mar 2026, 20:13 UTC

Earnings

Oracle Raised $30 B Through Combination of Investment Grade Bonds and Mandatory Convertible Preferred Stk Within Days of Feb Announcement >ORCL

DJ

Read

10 mar 2026, 20:12 UTC

Earnings

Oracle Stock Jumps on Earnings Beat -- Barrons.com

DJ

Read

Peer Comparison

Price change

Karyopharm Therapeutics Inc Forecast

Price Target

By TipRanks

129.68% upside

12 Months Forecast

Average 19.5 USD  129.68%

High 28 USD

Low 12 USD

Based on 5 Wall Street analysts offering 12 month price targets forKaryopharm Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Based on 5 analysts giving stock ratings to Karyopharm Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

5.9501 / 7.66Support & Resistance

Short Term

Bullish Evidence

Recent bullish events outweigh bearish events.

Intermediate Term

Strong Bearish Evidence

All events are bearish.

Long Term

No Evidence

There are no events.

Sentiment

By Acuity

316 / 351 Ranking in Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

Other stocks from the sector

LLY

Eli Lilly and Co.

1,000.74

↓-0.73%

JNJ

Johnson and Johnson

243.67

↑ +0.49%

ABBV

AbbVie Inc

226.66

↓-0.51%

NVS

Novartis AG

161.54

↓-0.79%

AZN

AstraZeneca PLC

195.13

↑ +0.21%
help-icon Live chat